Physician profile
Erin Mcfadden
NPI 1932369626
$1,725.35
in general payments reported to CMS, 2019-2025
19 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.31 · 2021: $74.47 · 2022: $105 · 2023: $571 · 2024: $684 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.10 | 2022-2025 | |
| Braeburn INC. | $216.55 | 2023-2025 | Brixadi |
| Astrazeneca Pharmaceuticals LP | $214.21 | 2023-2024 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $211.17 | 2024-2025 | Repatha, Otezla, Repatha |
| Medtronic, INC. | $170.19 | 2022-2025 | Minimed 780g, Minimed 770g |
| Glaxosmithkline, LLC. | $117.60 | 2021-2024 | Arexvy, Rotarix, Bexsero |
| Alkermes, INC. | $82.27 | 2021-2024 | Aristada, Lybalvi |
| Novo Nordisk INC | $80.77 | 2022-2025 | Wegovy |
| Astellas Pharma US INC | $67.94 | 2023-2024 | Veozah |
| Indivior INC. | $64.79 | 2023-2025 | Sublocade |
| Pfizer INC. | $47.04 | 2022-2023 | |
| Dexcom, INC. | $22.30 | 2024 | Dexcom G6 Transmitter |
| Abiomed | $21.48 | 2024 | Impella |
| Sumitomo Pharma America, INC. | $16.60 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $15.07 | 2023 | Aptima |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.90 | 2020 | |
| Insulet Corporation | $14.89 | 2023 | Omnipod |
| Sanofi-Aventis U.S. LLC | $12.41 | 2020 | |
| Endogastric Solutions, INC | $10.07 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Mcfadden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.